Bringing Innovation in Bioequivalence Studies: Evaluating Multiple Test Formulations in a Single Crossover Pivotal Bioequivalence Study Using Multiplicity Correction.

Authors

Chandra Teja Uppuluri, Rajkumar Boddu, Sohel Mohammed Khan, Anuj Kumar Saini, Sivacharan Kollipara

Published in

Journal of clinical pharmacology. Volume 66. Issue 11.

Abstract

ICH M13A recognizes higher-order bioequivalence (BE) studies involving multiple test or comparator products. When any one of several test formulations may independently demonstrate BE and support subsequent selection, multiplicity adjustment is required to control the family-wise type I error rate. This requirement introduces a practical penalty through increased sample-size requirements, wider confidence intervals, and a narrower range of test-to-reference geometric mean ratios that would result in BE conclusions. Although the statistical foundations of multiplicity correction are well established, the available literature has focused predominantly on methodological procedures, with limited consideration of the practical questions encountered during pharmaceutical product development. This review briefly summarizes the regulatory and statistical background and presents a scenario-based evaluation of the consequences of multiplicity in multi-formulation crossover BE studies. Analytical assessments were used to quantify sample-size inflation, confidence interval widening, and contraction of the T/R range that would result in a BE conclusion. Simulated BE study datasets complemented these evaluations, analyzed using full-data pooled-MSE (mean squared error) and separate pairwise ANOVA (analysis of variance) approaches and four multiplicity strategies: no adjustment, Bonferroni, Holm, and Hochberg for multiplicity adjustment. The review provides a practical framework for balancing statistical penalty against the value of preserving the ability to retain more than one formulation candidate within a single pivotal study or development. The present evaluation is restricted to non-replicate crossover BE studies.

PMID:
42973152
Bibliographic data and abstract were imported from PubMed on 03 Nov 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.